ASSEMBLY BIOSCIENCES, INC. (ASMB): Nasdaq/NYSE listing notice — Assembly Biosciences receives Nasdaq bid-price deficiency notice

ASSEMBLY BIOSCIENCES, INC.

Nasdaq notified ASMB that bid price closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until March 25, 2024, to regain compliance.
Compliance requires closing bid price ≥$1.00 for ten consecutive business days.
If not cured, may be eligible for second 180-day period with reverse stock split option.
Stock continues trading on Nasdaq Global Select under 'ASMB' with no immediate effect.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ASSEMBLY BIOSCIENCES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

September 27, 2023, Assembly Biosciences, Inc. (the "Company") received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") notifying the Company that, as the bid price for the Company's common stock, par value $0.001 per share (the "Common Stock"), had closed below $1.00 per share for the last 30 consecutive business days, the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. Nasdaq's notice has no immediate effect on the listing of the Co

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-050808

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.